Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry

References

• Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–10. doi:10.1038/nri2206. PMID: 18064051.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Treffers L, Plomp R, Bentlage AEH, De Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of fc-receptor- and complement-mediated-effector activities. Front Immunol. 2017;8(877). doi:10.3389/fimmu.2017.00877. PMID: 28824618.
   Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669–74. doi:10.1073/pnas.1108455108. PMID: 21768335.
   PubMed Web of Science ®Google Scholar
• Radaev S, Motyka S, Fridman W-H, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. J Biol Chem. 2001;276(19):16469–77. doi:10.1074/jbc.M100350200. PMID: 11297532.
   PubMed Web of Science ®Google Scholar
• Barb AW. Fc γ receptor compositional heterogeneity: considerations for immunotherapy development. J Biol Chem. 2021;296:100057. PMID: 33172893. doi:10.1074/jbc.REV120.013168.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34. doi:10.1038/nrd2804. PMID: 19247305.
   PubMed Web of Science ®Google Scholar
• Kerntke C, Nimmerjahn F, Biburger M. There is (scientific) strength in numbers: a comprehensive quantitation of Fc gamma receptor numbers on human and murine peripheral blood leukocytes. Front Immunol. 2020;11(118). doi:10.3389/fimmu.2020.00118. PMID: 32117269.
   PubMedGoogle Scholar
• Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91. doi:10.1182/blood-2013-05-504043. PMID: 24106207.
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. mAbs. 2016;8(8):1512–24. doi:10.1080/19420862.2016.1218586. PMID: 27492264.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34. doi:10.1093/glycob/cwv065. PMID: 26263923.
   PubMed Web of Science ®Google Scholar
• Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291–305. doi:10.1016/j.biologicals.2016.06.005. PMID: 27461239.
   PubMed Web of Science ®Google Scholar
• Roberts JT, Barb AW. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. J Biol Chem. 2018;293(51):19899–908. doi:10.1074/jbc.RA118.005273. PMID: 30361439.
   PubMed Web of Science ®Google Scholar
• Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. Immunol Rev. 2015;268(1):201–21. doi:10.1111/imr.12365. PMID: 26497522.
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–25. doi:10.1182/blood-2008-09-179754. PMID: 19018092.
   PubMed Web of Science ®Google Scholar
• Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, Repp R, van Berkel PHC, Vink T, van de Winkel JGJ. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008;112(6):2390–99. doi:10.1182/blood-2008-03-144600. PMID: 18566325.
   PubMed Web of Science ®Google Scholar
• De Taeye SW, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, Sénard T, Salehi N, Wuhrer M, Schuurman J. FcγR binding and ADCC activity of human IgG allotypes. Front Immunol. 2020;11(740). doi:10.3389/fimmu.2020.00740. PMID: 32435243.
   Google Scholar
• Subedi GP, Barb AW. CD16a with oligomannose-type N-glycans is the only “low-affinity” Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro. J Biol Chem. 2018;293(43):16842–50. doi:10.1074/jbc.RA118.004998. PMID: 30213862.
   PubMed Web of Science ®Google Scholar
• Lippold S, Nicolardi S, Domínguez-Vega E, Heidenreich A-K, Vidarsson G, Reusch D, Haberger M, Wuhrer M, Falck D. Glycoform-resolved FcɣRIIIa affinity chromatography–mass spectrometry. mAbs. 2019;11(7):1191–96. doi:10.1080/19420862.2019.1636602. PMID: 31276431.
   PubMed Web of Science ®Google Scholar
• Lippold S, Nicolardi S, Wuhrer M, Falck D. Proteoform-resolved FcɤRIIIa binding assay for fab glycosylated monoclonal antibodies achieved by affinity chromatography mass spectrometry of Fc moieties. Front Chem. 2019;7(698). doi:10.3389/fchem.2019.00698. PMID: 31709228.
   PubMedGoogle Scholar
• Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One. 2015;10(12):e0143520. doi:10.1371/journal.pone.0143520. PMID: 26657484.
   PubMed Web of Science ®Google Scholar
• Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Rüger P, Reusch D. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One. 2015;10(8):e0134949. doi:10.1371/journal.pone.0134949. PMID: 26266936.
   PubMed Web of Science ®Google Scholar
• Cymer F, Beck H, Rohde A, Reusch D. Therapeutic monoclonal antibody N-glycosylation – structure, function and therapeutic potential. Biologicals. 2018;52:1–11. PMID: 29239840. doi:10.1016/j.biologicals.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Wojcik I, Sénard T, de Graaf EL, Janssen GMC, De Ru AH, Mohammed Y, Van Veelen PA, Vidarsson G, Wuhrer M, Falck D. Site-specific glycosylation mapping of Fc gamma receptor IIIb from neutrophils of individual healthy donors. Anal Chem. 2020;92(19):13172–81. doi:10.1021/acs.analchem.0c02342. PMID: 32886488.
   PubMed Web of Science ®Google Scholar
• Choo MS, Wan C, Rudd PM, Nguyen-Khuong T. GlycopeptideGraphMS: improved glycopeptide detection and identification by exploiting graph theoretical patterns in mass and retention time. Anal Chem. 2019;91(11):7236–44. doi:10.1021/acs.analchem.9b00594. PMID: 31079452.
   PubMed Web of Science ®Google Scholar
• MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966–68. doi:10.1093/bioinformatics/btq054. PMID: 20147306.
   PubMed Web of Science ®Google Scholar
• Freimoser–Grundschober A, Rueger P, Fingas F, Sondermann P, Herter S, Schlothauer T, Umana P, Neumann C. FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies. J Chromatogr A. 2020;1610:460554. PMID: 31597603. doi:10.1016/j.chroma.2019.460554.
   PubMed Web of Science ®Google Scholar
• Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, JT R. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. J Proteome Res. 2011;10(7):3031–39. doi:10.1021/pr1012653. PMID: 21561106.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457–66. doi:10.1093/protein/gzw040. PMID: 27578889.
   PubMed Web of Science ®Google Scholar
• Umaña P, Jean–Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17(2):176–80. doi:10.1038/6179. PMID: 10052355.
   PubMed Web of Science ®Google Scholar
• Cymer F, Thomann M, Wegele H, Avenal C, Schlothauer T, Gygax D, Beck H. Oxidation of M252 but not M428 in hu-IgG1 is responsible for decreased binding to and activation of hu-FcγRIIa (His131). Biologicals. 2017;50:125–28. PMID: 28988621. doi:10.1016/j.biologicals.2017.09.006.
   PubMed Web of Science ®Google Scholar
• Hayes JM, Frostell A, Karlsson R, Müller S, Martín SM, Pauers M, Reuss F, Cosgrave EF, Anneren C, Davey GP. Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics. 2017;16(10):1770–88. doi:10.1074/mcp.M117.066944. PMID: 28576848.
   PubMed Web of Science ®Google Scholar
• Cambay F, Forest-Nault C, Dumoulin L, Seguin A, Henry O, Durocher Y, De Crescenzo G. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms. Mol Immunol. 2020;121:144–58. PMID: 32222585. doi:10.1016/j.molimm.2020.03.010.
   PubMed Web of Science ®Google Scholar
• Chu TH, Patz EF, Ackerman ME. Coming together at the hinges: therapeutic prospects of IgG3. mAbs. 2021;13(1):1882028. doi:10.1080/19420862.2021.1882028. PMID: 33602056.
   PubMed Web of Science ®Google Scholar
• Wei B, Gao X, Cadang L, Izadi S, Liu P, Zhang H-M, Hecht E, Shim J, Magill G, Pabon JR. Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation. mAbs. 2021;13(1):1893427. doi:10.1080/19420862.2021.1893427. PMID: 33682619.
   PubMed Web of Science ®Google Scholar
• Thijs LJ, Van Osch JN, Derksen NIL, van Mierlo G, Ellen van der Schoot C, Wuhrer M, Rispens T, Vidarsson G. Fc galactosylation promotes hexamerization of human IgG1, leading to enhanced classical complement activation. Journal of Immunology (Baltimore, Md: 1950). 2021. doi:10.4049/jimmunol.2100399. PMID: 34408013.
   Google Scholar
• Aoyama M, Hashii N, Tsukimura W, Osumi K, Harazono A, Tada M, Kiyoshi M, Matsuda A, Ishii-Watabe A. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies. mAbs. 2019;11(5):826–36. doi:10.1080/19420862.2019.1608143. PMID: 30990348.
   PubMed Web of Science ®Google Scholar
• Yogo R, Yamaguchi Y, Watanabe H, Yagi H, Satoh T, Nakanishi M, Onitsuka M, Omasa T, Shimada M, Maruno T. The fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III. Sci Rep. 2019;9(1):11957. doi:10.1038/s41598-019-48323-w. PMID: 31420591.
   PubMedGoogle Scholar
• Sun Y, Izadi S, Callahan M, Deperalta G, Wecksler AT. Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity. J Biol Chem. 2021;297(1):100826. doi:10.1016/j.jbc.2021.100826. PMID: 34044019.
   PubMed Web of Science ®Google Scholar
• de Haan N, Falck D, Wuhrer M. Monitoring of immunoglobulin N- and O-glycosylation in health and disease. Glycobiology. 2019;30(4):226–40. doi:10.1093/glycob/cwz048. PMID: 31281930.
   Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs. 2013;5(4):576–86. doi:10.4161/mabs.24981. PMID: 23765230.
   PubMed Web of Science ®Google Scholar
• Evans AR, Capaldi MT, Goparaju G, Colter D, Shi FF, Aubert S, Li L-C, Mo J, Lewis MJ, Hu P. Using bispecific antibodies in forced degradation studies to analyze the structure–function relationships of symmetrically and asymmetrically modified antibodies. mAbs. 2019;11(6):1101–12. doi:10.1080/19420862.2019.1618675. PMID: 31161859.
   PubMed Web of Science ®Google Scholar
• Lu X, Machiesky LA, De Mel N, Du Q, Xu W, Washabaugh M, Jiang X-R, Wang J. Characterization of IgG1 Fc deamidation at asparagine 325 and its impact on antibody-dependent cell-mediated cytotoxicity and FcγRIIIa binding. Sci Rep. 2020;10(1):383. doi:10.1038/s41598-019-57184-2. PMID: 31941950.
   PubMed Web of Science ®Google Scholar
• Bahou C, Love EA, Leonard S, Spears RJ, Maruani A, Armour K, Baker JR, Chudasama V. Disulfide modified IgG1: an investigation of biophysical profile and clinically relevant Fc interactions. Bioconjug Chem. 2019;30(4):1048–54. doi:10.1021/acs.bioconjchem.9b00174. PMID: 30855134.
   PubMed Web of Science ®Google Scholar
• Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. mAbs. 2014;6(2):409–21. doi:10.4161/mabs.27457. PMID: 24492248.
   PubMed Web of Science ®Google Scholar
• Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S. FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol. 2019;9:3124–3124. PMID: 30761158. doi:10.3389/fimmu.2018.03124.
   PubMed Web of Science ®Google Scholar
• García-García E, Nieto-Castañeda G, Ruiz-Saldaña M, Mora N, Rosales C. FcγRIIA and FcγRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. Journal of Immunology (Baltimore, Md: 1950). 2009;182(8):4547–56. doi:10.4049/jimmunol.0801468. PMID: 19342628.
   PubMed Web of Science ®Google Scholar
• Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108. doi:10.1038/nri3582. PMID: 24445665.
   PubMed Web of Science ®Google Scholar
• Weber F, Breustedt D, Schlicht S, Meyer CA, Niewoehner J, Ebeling M, Freskgard PO, Bruenker P, Singer T, Reth M. First infusion reactions are mediated by FcγRIIIb and neutrophils. Pharm Res. 2018 Jun 27;35(9):169. doi:10.1007/s11095-018-2448-8. PMID: 29951887; PubMed Central PMCID: PMCPMC6021477.
   PubMed Web of Science ®Google Scholar